You are viewing the site in preview mode

Skip to main content


Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Fig. 2

Current landscape of combination immunotherapy trials for various tumor histologies. a Number of combination checkpoint inhibition trials for various tumor histologies. Abbreviations: NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma; GEJ, gastro-esophageal junction; MDS, myelodysplastic syndrome. b Landscape of combination checkpoint inhibition agents. Legend: The figure elaborates relative number of trials for four combinations of immunotherapy agents. Nivolumab plus ipilimumab: 62% (101 trials), pembrolizumab plus ipilimumab 4% (6 trials), tremelimumab plus durvalumab 34% (55 trials) and atezolizumab plus ipilimumab <‚ÄČ1% (1 trial)

Back to article page